Hengrui Pharmaceutical announced that recently, its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for adbelimab injections and SHR-8068 injections, and will conduct clinical trials in the near future.

On January 30, 2024 Hengrui Pharmaceutical reported that its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a "Pharmaceutical Clinical Trial Approval Notice" for adbelimab injections and SHR-8068 injections, and will conduct clinical trials in the near future (Press release, Shanghai Shengdi Pharmaceutical, JAN 30, 2024, View Source [SID1234651778]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!